TransMedics Group (NASDAQ:TMDX) Given New $109.00 Price Target at Needham & Company LLC

by · The Cerbat Gem

TransMedics Group (NASDAQ:TMDX – Free Report) had its price objective reduced by Needham & Company LLC from $208.00 to $109.00 in a research note published on Tuesday, MarketBeat.com reports. Needham & Company LLC currently has a buy rating on the stock.

Other analysts have also issued research reports about the stock. Morgan Stanley lifted their price objective on shares of TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Piper Sandler reissued an “overweight” rating and issued a $180.00 price objective on shares of TransMedics Group in a research note on Monday, October 7th. Oppenheimer boosted their price target on shares of TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, August 1st. Canaccord Genuity Group raised their target price on TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Finally, Stephens upped their price target on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $144.80.

View Our Latest Stock Report on TransMedics Group

TransMedics Group Price Performance

Shares of TMDX opened at $82.40 on Tuesday. The stock has a market cap of $2.77 billion, a PE ratio of 87.66 and a beta of 1.99. The company has a quick ratio of 8.48, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The business has a 50-day simple moving average of $140.51 and a two-hundred day simple moving average of $139.29. TransMedics Group has a 12-month low of $38.13 and a 12-month high of $177.37.

TransMedics Group (NASDAQ:TMDX – Get Free Report) last announced its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. During the same period in the previous year, the firm posted ($0.12) earnings per share. The firm’s quarterly revenue was up 63.7% compared to the same quarter last year. Analysts anticipate that TransMedics Group will post 1.11 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other TransMedics Group news, Director James R. Tobin sold 20,000 shares of the stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $159.33, for a total value of $3,186,600.00. Following the completion of the sale, the director now owns 173,146 shares in the company, valued at approximately $27,587,352.18. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the transaction, the chief executive officer now owns 61,643 shares in the company, valued at approximately $9,457,269.06. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director James R. Tobin sold 20,000 shares of TransMedics Group stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $159.33, for a total value of $3,186,600.00. Following the transaction, the director now owns 173,146 shares of the company’s stock, valued at $27,587,352.18. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 61,247 shares of company stock worth $9,518,181. 7.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. International Assets Investment Management LLC purchased a new position in shares of TransMedics Group in the second quarter worth $47,000. USA Financial Formulas purchased a new stake in TransMedics Group during the third quarter valued at $55,000. J.Safra Asset Management Corp increased its position in TransMedics Group by 649.2% during the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after acquiring an additional 383 shares during the last quarter. Signaturefd LLC increased its position in TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after acquiring an additional 93 shares during the last quarter. Finally, Fidelis Capital Partners LLC purchased a new stake in TransMedics Group during the first quarter valued at $35,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About TransMedics Group

(Get Free Report)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Read More